Advertisement

Deep Integrated Biomarkers of Aging

  • Polina Mamoshina
  • Alex ZhavoronkovEmail author
Chapter
Part of the Healthy Ageing and Longevity book series (HAL, volume 10)

Abstract

Recent advances in deep learning (DL) and other machine learning methods (ML) and the availability of large population data sets annotated with age and other features led to the development of the many predictors of chronological age frequently referred to as the deep aging clocks (DACs). Many of these aging clocks were pioneered by Insilico Medicine and are available for testing online via www.young.ai, www.aging.ai, and other resources. Several of the DACs demonstrate biological relevance and can be used for a variety of applications ranging from aging and disease target identification, identifying the age-related features implicated in diseases, the inference of causal graphs, analyze the population-specificity of the data type and analyze the mechanism of drug response and many others. The generative adversarial networks (GANs) can be used to synthesize new data of patients of specified ages in large volume providing for novel target identification techniques, as well as for anonymization and patient privacy methods. In this chapter we provide a brief overview of the DACs, their advantages, and disadvantages as well as the commentary on the challenges in this emerging field.

Notes

Acknowledgements

The authors would like to thank Nvidia Corporation and personally Mark Berger for providing early access to the graphics processing units (GPUs) that helped power the development of the DACs.

Conflict of Interest

AZ and PM work for Insilico Medicine, a for-profit longevity biotechnology company developing the end-to-end target identification and drug discovery pipeline for a broad spectrum of age-related diseases. The company applied for multiple patents covering the various methods for development and applications of the aging clocks. The company may have commercial interests in this publication.

References

  1. Aliper, A. et al. (2016) In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state. Aging (Albany. NY). 8, 2127–2152CrossRefGoogle Scholar
  2. Aliper, A. et al. (2017) Towards natural mimetics of metformin and rapamycin. Aging (Albany. NY). 9, 2245–2268CrossRefGoogle Scholar
  3. Aliper A et al (2016) Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. Mol. Pharm. 13:2524–2530CrossRefGoogle Scholar
  4. Artemov, A. V et al. (2016) Integrated deep learned transcriptomic and structure-based predictor of clinical trials outcomes. bioRxiv  https://doi.org/10.1101/095653
  5. Bakula, D. et al. (2018) Aging and drug discovery. Aging (Albany. NY). 10, 3079–3088CrossRefGoogle Scholar
  6. Bobrov, E. et al. (2018) PhotoAgeClock: deep learning algorithms for development of non-invasive visual biomarkers of aging. Aging (Albany. NY). 10, 3249–3259CrossRefGoogle Scholar
  7. Cole JH et al (2017) Predicting brain age with deep learning from raw imaging data results in a reliable and heritable biomarker. Neuroimage 163:115–124CrossRefGoogle Scholar
  8. Galkin, F. et al. (2018) Human microbiome aging clocks based on deep learning and tandem of permutation feature importance and accumulated local effects. bioRxiv  https://doi.org/10.1101/507780
  9. Horvath S (2013) DNA methylation age of human tissues and cell types. Genome Biol. 14:R115CrossRefGoogle Scholar
  10. Kadurin A et al (2017a) The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology. Oncotarget 8:10883–10890Google Scholar
  11. Kadurin A et al (2017b) druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico. Mol. Pharm. 14:3098–3104CrossRefGoogle Scholar
  12. LeCun Y et al (2015) Deep learning. Nature 521:436CrossRefGoogle Scholar
  13. Lee H et al (2017) Fully Automated Deep Learning System for Bone Age Assessment. J. Digit. Imaging 30:427–441CrossRefGoogle Scholar
  14. Mamoshina P et al (2016) Applications of Deep Learning in Biomedicine. Mol. Pharm. 13:1445–1454CrossRefGoogle Scholar
  15. Mamoshina P et al (2018a) Population Specific Biomarkers of Human Aging: A Big Data Study Using South Korean, Canadian, and Eastern European Patient Populations. Journals Gerontol. Ser. A 73:1482–1490CrossRefGoogle Scholar
  16. Mamoshina P et al (2018b) Blood Biochemistry Analysis to Detect Smoking Status and Quantify Accelerated Aging in Smokers. Sci. Rep, Accepted proofGoogle Scholar
  17. Mamoshina P et al (2018c) Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification. Front. Genet. 9:242Google Scholar
  18. Miotto R et al (2016) Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records. Sci. Rep. 6:26094CrossRefGoogle Scholar
  19. Polykovskiy D et al (2018) Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery. Mol. Pharm. 15:4398–4405CrossRefGoogle Scholar
  20. Putin E et al (2016) Deep biomarkers of human aging: Application of deep neural networks to biomarker development. 8:1–13Google Scholar
  21. Putin E et al (2018a) Adversarial Threshold Neural Computer for Molecular de Novo Design. Mol. Pharm. 15:4386–4397CrossRefGoogle Scholar
  22. Putin E et al (2018b) Reinforced Adversarial Neural Computer for de Novo Molecular Design. J. Chem. Inf. Model. 58:1194–1204CrossRefGoogle Scholar
  23. Pyrkov TV et al (2018) Extracting biological age from biomedical data via deep learning: too much of a good thing? Sci. Rep. 8:5210CrossRefGoogle Scholar
  24. Song, J. et al. (2017) Dual Conditional GANs for Face Aging and RejuvenationGoogle Scholar
  25. Zhavoronkov A et al (2014) Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49CrossRefGoogle Scholar
  26. Zhavoronkov A (2018) Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. Mol. Pharm. 15:4311–4313CrossRefGoogle Scholar
  27. Zhavoronkov A et al (2019) Artificial intelligence for aging and longevity research: Recent advances and perspectives. Ageing Res. Rev. 49:49–66CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Insilico Medicine Hong Kong LimitedScience ParkHong Kong
  2. 2.Computer Science DepartmentUniversity of OxfordOxfordUK
  3. 3.The Buck Institute for Research on AgingNovatoUSA
  4. 4.The Biogerontology Research FoundationLondonUK

Personalised recommendations